British Land and Royal London Asset Management have let 50,000 sq ft to global biopharmaceutical company Gilead Sciences at One Triton Square, Regent’s Place.
The building, which provides more than 300,000 sq ft of sustainable, purpose-built space, including fitted laboratories, Storey flexible workspace, premium offices and shared meeting and event facilities, is now 77% let or under offer by ERV.
Kelly Cleveland, head of real estate at British Land, said: “Gilead’s commitment to One Triton Square reflects the quality of this exceptional building and the ecosystem we are creating at Regent’s Place. The campus is the place where innovative businesses come to scale, delivering next-generation technologies in a vibrant, future-focused location. The success of the building reinforces our conviction in taking strategic surrender premiums, upgrading space and securing high quality lettings that unlock superior rents.”
Mark Evans, head of property at Royal London Asset Management, added: “We are delighted with the leasing success of One Triton Square following the building launch at the end of 2025 and are pleased to welcome Gilead Sciences to the development. One Triton Square represents a marquee investment for RLAM Property following the creation of the 50/50 JV in March 2024 and is a key pillar to our evolving life science portfolio across Oxford, Cambridge and London.
“The leasing momentum the team have established, stands to deliver strong investment returns to the fund and provides conviction for our underlying investment philosophy of deploying at scale into prime buildings in core, well-connected markets.”
